Brief: MAIA Biotechnology Says Co's THIO-101 Phase 2 Clinical Trial Nears Completion
05/03/2024 15:02
March 5 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY INC - THIO-101 PHASE 2 CLINICAL TRIAL
NEARS
COMPLETION; SURVIVAL AND RESPONSE DATA UPDATES FORTHCOMING.
Source text for Eikon: ID:nBwb7HQxZa
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale